M&A Deal Summary |
|
|---|---|
| Date | 2025-05-14 |
| Target | Efimosfermin |
| Sector | Life Science |
| Buyer(s) | GSK |
| Sellers(s) | Boston Pharmaceuticals |
| Deal Type | Divestiture |
| Deal Value | 1.2B USD |
SEARCH BY
| Category | Company |
|---|---|
| Founded | 1715 |
| Sector | Life Science |
| Employees | 68,629 |
| Revenue | 31.4B GBP (2024) |
GSK is a multinational pharmaceutical, biologics, vaccines and consumer healthcare company. GSK was founded in 1715 and is based in Brentford, United Kingdom.
| DEAL STATS | # |
|---|---|
| Overall | 34 of 35 |
| Sector: Life Science M&A | 28 of 28 |
| Type: Divestiture M&A Deals | 6 of 7 |
| State: Massachusetts M&A | 5 of 5 |
| Country: United States M&A | 21 of 21 |
| Year: 2025 M&A | 2 of 3 |
| Size (of disclosed) | 12 of 31 |
| DATE | TARGET | DEAL TYPE | VALUE |
|---|---|---|---|
| 2025-01-13 |
IDRx
Cambridge, Massachusetts, United States IDRx is a clinical-stage biopharmaceutical company dedicated to transforming cancer care with intelligently designed precision therapies. IDRx was founded in 2022 and is based in Cambridge, Massachusetts. |
Buy | $1.2B |
| DATE | TARGET | DEAL TYPE | VALUE |
|---|---|---|---|
| 2025-06-02 |
Trelegy Ellipta
London, United Kingdom Trelegy Ellipta is a prescription inhaled medication formulated for the long-term maintenance treatment of chronic obstructive pulmonary disease, including emphysema and chronic bronchitis, and, in some instances, for asthma in adults. Trelegy Ellipta is based in London, United Kingdom. |
Buy | $225M |
| Category | Company |
|---|---|
| Founded | 2016 |
| Sector | Life Science |
Boston Pharmaceuticals is a clinical-stage biopharmaceutical company focused on developing highly engineered therapies to transform the lives of patients who fight serious liver diseases. Boston Pharmaceuticals was founded in 2016 and is based in Cambridge, Massachusetts.
| DEAL STATS | # |
|---|---|
| Overall | 1 of 1 |
| Sector: Life Science M&A | 1 of 1 |
| Type: Divestiture M&A Deals | 1 of 1 |
| State: Massachusetts M&A | 1 of 1 |
| Country: United States M&A | 1 of 1 |
| Year: 2025 M&A | 1 of 1 |
| Size (of disclosed) | 1 of 1 |
